This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Icosavax (ICVX) Up on Positive VLP Vaccine Candidate Data
by Zacks Equity Research
Icosavax (ICVX) surges on positive data from the clinical study of IVX-A12, targeting respiratory syncytial virus and human metapneumovirus in older adults.
Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now
by Zacks Equity Research
Puma Biotechnology (PBYI), a top-ranked stock, has a promising development candidate, alisertib. Its only marketed product, Nerlynx (neratinib), is witnessing improving demand trends in the United States.
Wall Street Analysts Think Omega Therapeutics, Inc. (OMGA) Could Surge 48.23%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Omega Therapeutics, Inc. (OMGA) points to a 48.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Omega Therapeutics, Inc. (OMGA) delivered earnings and revenue surprises of 21.88% and 31.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Omega Therapeutics, Inc. (OMGA) Surges 19.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Omega Therapeutics, Inc. (OMGA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Omega Therapeutics, Inc. (OMGA) Moves 15.2% Higher: Will This Strength Last?
by Zacks Equity Research
Omega Therapeutics, Inc. (OMGA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Omega Therapeutics, Inc. (OMGA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omega Therapeutics, Inc. (OMGA) delivered earnings and revenue surprises of -3.23% and 13.08%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Revance Therapeutics, Inc. (RVNC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -75% and 6.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Omega Therapeutics, Inc. (OMGA) Surges 37.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Omega Therapeutics, Inc. (OMGA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts Think Omega Therapeutics, Inc. (OMGA) Could Surge 136%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Omega Therapeutics, Inc. (OMGA) points to a 135.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Omega Therapeutics, Inc. (OMGA) Could Rally 229%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 229.3% upside potential for Omega Therapeutics, Inc. (OMGA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Encompass Health (EHC) Forms JV With NCH Healthcare in Naples
by Zacks Equity Research
The NCH Healthcare System's board grants approval to invest in the joint venture with Encompass Health (EHC).
Encompass Health (EHC) Plans to Distribute Enhabit Shares
by Zacks Equity Research
Every Encompass Health (EHC) shareholder will receive one Enhabit common share for every two EHC common shares held.
Should You Hold On to Teladoc Health (TDOC) Stock for Now?
by Zacks Equity Research
Teladoc Health's (TDOC) cash flows will likely gain from the growing number of visits and memberships.
HCA Healthcare's (HCA) Galen College Adds 8th New Facility
by Zacks Equity Research
HCA Healthcare's (HCA) Galen College nursing campus addition comes when the country is suffering from a nursing shortage.
Here's Why Investors Should Bet on Cigna (CI) Stock Now
by Zacks Equity Research
Cigna (CI) expects 2022 medical customers to grow by a minimum of 725,000, suggesting an upside from the prior projection.
UnitedHealth (UNH) Rewards Shareholders With 13.8% Dividend Hike
by Zacks Equity Research
UnitedHealth's (UNH) strong balance sheet supports its endeavors to return shareholders' funds.
Encompass Health (EHC) Updates 2022 Guidance: Dips 5.4%
by Zacks Equity Research
Encompass Health (EHC) expects to retain its cash dividend routine. However, the amount might decline to reflect the spin-off of the home health and hospice business.
Ensign Group (ENSG) Up 3.7% in 30 Days: More Room to Rally?
by Zacks Equity Research
Ensign Group's (ENSG) rising profits from Skilled Services business are a major positive.
The Joint (JYNT) Acquires 4 Franchised Facilities, Down 5%
by Zacks Equity Research
The Joint (JYNT) anticipates the new acquisition value in Scottsdale to match the price of its previous purchases.
Omega Therapeutics, Inc. (OMGA) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Omega Therapeutics, Inc. (OMGA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.